DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Kilitch Drugs (India) Limited — Outcome of Board Meeting

NSE 1 hr ago·6 Nov 2026, 3:19 pm

Kilitch Drugs India

Kilitch Drugs (India) Limited has informed the stock exchanges regarding its financial results for the period ending September 30, 2026. This disclosure follows the company's scheduled board meeting, which reviewed the performance of its pharmaceutical business during this quarter.

For investors, this update is a key milestone as it provides the first official data on the company's current financial health. It allows stakeholders to assess the company's revenue trajectory and operational efficiency, which are critical factors in evaluating its growth potential.

Investors should focus on the specific figures for revenue and profit margins in the filing. Monitoring how these numbers compare to market expectations and previous quarters will be essential to gauge the company's performance and future strategy.